Side effects and treatments of Mobotinib (Mobosetinib)

Mobocertinib (Mobocertinib) is mainly used to treat non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) exon 20 insertion mutations. Althoughmobosetinibhas shown significant efficacy in delaying disease progression and improving patient prognosis, a variety of side effects may occur during its use. Understanding these side effects and how to manage them is critical for patients and health care providers.

Common side effects and their treatments

1. Digestive tract reaction

Symptoms: Gastrointestinal side effects are one of the most common side effects of mobosetinib , including diarrhea, nausea, vomiting, stomatitis and loss of appetite. Diarrhea is the most common symptom and may affect patients' quality of daily life.

Processing:

Diarrhea: Mild diarrhea can be relieved by adjusting your diet and increasing your fluid intake. Moderate to severe diarrhea requires the use of an antidiarrheal medication such as loperamide. In severe cases of severe diarrhea, medication may need to be temporarily discontinued and intravenous fluids given.

Nausea and vomiting: Antiemetics such as olanzapine or ondansetron may be used, and patients are advised to eat small, frequent meals and avoid greasy and spicy foods.

Stomatitis: Use mouthwash (such as chlorhexidine mouthwash) and oral care products to keep your mouth clean and avoid oral infections.

2. Skin reaction

Symptoms: Rush and dry skin are common skin side effects of mobosetinib . The rash usually appears as papules, pustules, or erythema and may be itchy and painful.

Processing:

Mild rash: Use a moisturizer and an anti-inflammatory ointment (such as one containing hydrocortisone).

Moderate to severe rash: Oral antibiotics and systemic steroids may be needed. Patients are advised to wear loose-fitting cotton clothing to avoid scratching and irritating the skin.

3. Abnormal liver function

Symptoms: Mobosertinib may cause an increase in liver enzyme levels (such as AST, ALT), manifesting as fatigue, jaundice, loss of appetite and other symptoms.

Processing:

Monitoring: Regular monitoring of liver function is key, especially early in treatment. If liver enzymes are found to be elevated, the drug dose should be adjusted or temporarily discontinued according to the situation.

Drug intervention: In severe cases, liver-protective drugs may be needed, and a decision should be made under the guidance of a doctor whether to continue taking the drug.

4. Abnormal kidney function

Symptoms: Use of mobosetinib may result in increased serum creatinine and decreased renal function. Patients may experience symptoms such as edema, decreased urine output, and high blood pressure.

Processing:

Monitoring: Regularly check kidney function indicators (such as blood creatinine and urea nitrogen) to detect problems early.

Dietary adjustment: Limit salt and protein intake and maintain proper hydration.

Drug adjustment: Adjust drug dosage according to renal function, suspend medication and perform renal function protection treatment if necessary.

Rare but serious side effects

1. Cardiotoxicity

Symptoms: Mobotinib may cause QT prolongation and cardiac arrhythmias. Patients may experience chest pain, palpitations, syncope and other symptoms.

Processing:

Monitoring: Periodically perform electrocardiograms, especially during treatment initiation and dose adjustments.

Drug adjustment: If QT interval is found to be prolonged, dosage adjustment or drug discontinuation should be considered, and cardioprotective treatment should be performed under the guidance of a doctor.

2. Pulmonary toxicity

Symptoms: Pulmonary toxicity manifests as interstitial lung disease (ILD) or pneumonia, and patients may experience symptoms such as cough, dyspnea, and fever.

Processing:

Early identification: If respiratory symptoms occur, chest imaging should be performed immediately.

Drug adjustment: After confirming pulmonary toxicity, the drug should be stopped immediately and anti-inflammatory treatment (such as steroids) should be carried out under the guidance of a doctor.

Mobocertinib (Mobocertinib) is a drug that targets EGFR exon 20Effective treatments for non-small cell lung cancer with insertional mutations, although bringing significant clinical benefits, may also cause a variety of side effects. While patients are using this drug, they need to undergo regular medical monitoring and promptly identify and deal with side effects to ensure the safety and effectiveness of the treatment. Patients should adjust their medications under the guidance of their doctors and take corresponding preventive and treatment measures to minimize the impact of side effects and improve their quality of life.